TrialsNest
Sign Up
Research Sites

Clinical trial recruitment follow-up SLA examples

Operational SLA examples for clinical trial recruitment follow-up, including first response, prescreen review, records requests, scheduling readiness, and stale-lead review.

Research SitesUpdated 2026-06-224 min read

A recruitment follow-up SLA should define how quickly each handoff is reviewed, who owns the next step, and when stale work is escalated before patient interest loses momentum.

Published Updated By TrialsNest editorial

Written for recruitment operations teams setting follow-up expectations. It is workflow education only and does not replace study-team review or patient-specific decisions.

Editorial review

How this resource is reviewed

Reviewed by TrialsNest clinical operations review on . Resource Hub pages are written for operational education and updated when workflow, buyer, or trust boundaries change.

This resource is operational education only and does not determine study eligibility, medical suitability, or enrollment. Authorized study teams make final study decisions.

Editorial policy

What to keep in view

Follow-up SLAs work best when they separate first response, prescreen review, records readiness, scheduling, and stale-lead escalation.
The SLA should create owner and due-date clarity without implying medical eligibility or guaranteed screening.
Weekly review should compare SLA misses by source, study, site, owner, blocker, and next action.

Questions to answer before acting on this guide

What does clinical trial recruitment follow-up SLA need to change in the daily workflow?
Which team owns the next action when a patient, site, or sponsor handoff stalls?
What signal would prove the workflow is improving instead of only adding more data?

How teams usually use it

Compare it with the real queue

Read it next to the way your team already works. The gaps usually show up around ownership, missing records, follow-up timing, or sponsor-update prep.

Mark the handoffs

For each section, ask where the work changes hands. If the handoff depends on memory, a spreadsheet tab, or a buried message, that is probably worth fixing.

Keep the boundary clear

When the topic touches matching or prescreening, keep the language careful. Early fit is not enrollment, and final study decisions stay with authorized study teams.

Resource focus

Why this page belongs in the Resource Hub

These notes make the page purpose, audience, and next path explicit so readers can understand how this guide differs from nearby resources.

Resource Hub

What this example page is meant to answer

This resource is focused on clinical trial recruitment follow-up SLA for research sites. It is designed to answer a narrow workflow question, then point readers to the adjacent TrialsNest pages that cover implementation, reporting, patient-facing trust, or product fit.

Use the example as proof, not a promise

Examples make recruiting operations easier to inspect. They should clarify what changed in the workflow while avoiding medical claims, guaranteed outcomes, or final eligibility language.

Where to go next inside TrialsNest

Use the related topic hub and selected next reads below to move deeper into the same search intent. Those links keep this page connected to a crawlable cluster instead of leaving it as an isolated article.

Focused next reads for this topic

These links keep the page inside the same practical topic path instead of sending readers through broad navigation.

See it in TrialsNest

Turn this guide into a working recruitment workflow.

Walk through how patient intake, prescreening, records readiness, scheduling, and reporting connect in the product.

Start with the moments where interest stalls

A clinical trial recruitment SLA should be built around handoffs, not abstract speed. The highest-risk points are usually first response, prescreen completion, coordinator review, records request, scheduling readiness, and stale-lead follow-up.

The goal is not to promise that every patient will screen or enroll. The goal is to make sure every patient inquiry has a clear owner, a timely next action, and a respectful close-out path when the study team determines the person should not continue.

Use practical SLA windows

A simple first version can set expectations like same-business-day ownership for new inquiries, one business day for first outreach, two business days for prescreen review after completion, two business days for records-request review, and a weekly stale-lead sweep.

Teams should adjust those windows by study complexity, staffing, visit burden, and source type. A high-touch referral source may need a different response expectation than a broad digital campaign, but both should still produce visible owner and next-action fields.

Define what counts as meaningful movement

A status update is not always meaningful movement. Useful movement includes first outreach attempted, patient responded, prescreen completed, records requested, records received, coordinator review completed, scheduling-ready, scheduled, closed as no response, or closed for an operational reason.

That definition keeps the SLA honest. If a lead is touched but no next action, due date, or owner changes, the team may still have a stale recruitment problem.

Review misses without blaming the queue

An SLA miss should start a workflow review. Was the issue source quality, coordinator capacity, missing records, unclear fit signals, scheduling constraints, or a patient who stopped responding? The answer decides the fix.

The weekly review should group misses by source, site, study, owner, blocker, and next action. That lets a site lead improve the workflow while keeping patient-specific details in the appropriate secure workspace.

Keep study-team boundaries clear

Follow-up SLAs should never imply that a patient is eligible, suitable, or guaranteed a screening visit. They only define the operational rhythm for reviewing interest and moving the next step forward when appropriate.

TrialsNest supports this kind of workflow by keeping source, owner, prescreen state, records readiness, stale risk, and next action visible. Authorized study teams still make final screening, eligibility, and enrollment decisions.

Site next step

Want this workflow organized in one place?

See how TrialsNest connects patient intake, prescreening, records readiness, coordinator follow-up, scheduling, and reporting for research sites.

Related TrialsNest workflows

These resource pages connect back to the product areas buyers usually ask about: public study search, site recruitment workflow, sponsor visibility, and the privacy-aware operating model.

Trust Center

Topics covered

clinical trial recruitment follow-up SLApatient recruitment follow-up timelineclinical trial lead follow upstale clinical trial leads

Common questions

What should teams know about clinical trial recruitment follow-up SLA?

A recruitment follow-up SLA should define how quickly each handoff is reviewed, who owns the next step, and when stale work is escalated before patient interest loses momentum. The practical value is in connecting the concept to ownership, follow-up, records readiness, scheduling, reporting, and clear next actions.

Who is this resource written for?

This resource is written for research sites sorting through practical questions around clinical trial recruitment follow-up SLA and the workflow decisions that usually come with it.

Does this guide replace study-team review or medical advice?

No. TrialsNest resources are educational and operational. They do not provide medical advice, diagnosis, treatment, emergency care, or final clinical trial eligibility decisions.

How would a team use this workflow guidance in practice?

Use it to compare the current workflow with what actually happens day to day: where leads wait, where records get lost, where follow-up slows down, and what needs a clearer owner. The best next step is to turn the article takeaways into a short review checklist for clinical trial recruitment follow-up SLA.

Trust and proof points

Study-team decisions stay with authorized teams

TrialsNest can organize intake, prescreening, and workflow context, but it does not make final eligibility, enrollment, treatment, or medical decisions.

Reporting focuses on operational movement

Sponsor-ready updates should show source quality, movement, blockers, and next actions without becoming a broad patient-detail workspace.

Public pages stay educational

These resources explain clinical recruiting workflows and buying decisions. Sensitive study details belong in the appropriate secure workflow.

!
Heads up
Medical and eligibility decisions stay with the study team
TrialsNest does not provide medical advice, diagnosis, treatment, emergency care, or final study eligibility decisions. Authorized study teams review each protocol and applicant.

Continue exploring

Helpful next reads

Follow-up reading chosen from the same topic cluster and audience context as this guide.

Cookie preferences
Learn more about cookies

Essential cookies keep the site working. Optional cookies help improve traffic and regional insights.